The problem of choosing an anticoagulant for stroke prevention in patients with atrial fibrillation
https://doi.org/10.21518/2079-701X-2014-12-58-64
Abstract
The article is a literature review on the problem of thromboembolic complications in non-valvular atrial fibrillation, the peculiarities of anticoagulant therapy and challenges associated with the selection of drugs for stroke prevention.
About the Authors
EL Dolgova
Saratov State Medical University named after VI Razumovskiy, the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
IM Sokolov
Saratov State Medical University named after VI Razumovskiy, the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
YG Schwarz
Saratov State Medical University named after VI Razumovskiy, the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest, 2010, 137: 263-272.
2. Stewart S, Murphy N, Walker A et al. Cost of an emerging epidemic. an economic analysis of atrial fibrillation in the UK. Heart, 2004, 90: 286-292.
3. Patel MR for ROCKET AF Executive Steering Committee. Stroke prevention using the oral direct factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF). Circulation, 2010, 122 (Suppl. 21): 2217.
4. Wadelius M, Chen LY, Downes K et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics, 2005, 5 (4): 262-70.
5. ACC/AHA/ESC Guidelines for the Management of Patients with Atrial Fibrillation. Eur Heart J 2010, 31: 2369-2429.
6. Feinberg WM, Cornell ES, Nightingale SD et al. Stroke Prevention in Atrial Fibrillation Investigators Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke 1997. 28: 1101-1106.
7. Kirchhof P, Auricchio A, Bax J et al. Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 2007, 28: 2803-2817.
8. Friberg J, Buch P, Scharling H, Gadsbphioll N et al. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003, 14: 666-672.
9. Levy S, Maarek M, Coumel P et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists Circulation, 1999, 99: 3028-3035.
10. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulations and Risk factors in Atrial Fibrillation (ATRIA) Study. JAMA, 2001, 285(18): 2370-5.
11. Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation. the Framingham Heart Study. Circulation 12004-, 110: 1042- 1046.
12. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009. 373. 155-166
13. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.JAMA 2001, 285: 2864-2870.
14. Hylek EM, Go AS, Chang Y et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003, 349: 1019-1026.
Review
For citations:
Dolgova E, Sokolov I, Schwarz Y. The problem of choosing an anticoagulant for stroke prevention in patients with atrial fibrillation. Meditsinskiy sovet = Medical Council. 2014;(12):58-64. (In Russ.) https://doi.org/10.21518/2079-701X-2014-12-58-64
Views:
324
Email this article 